H.R. 3731 · 119th Congress (2025–2027)
Small Biotech Innovation Act
To amend title XI of the Social Security Act to establish a research and development-intensive small biotech manufacturer exception from the Medicare drug price negotiation program.
CRS summary not yet available.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 3731’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. August Pfluger (R-TX-11)
- Cosponsors
4 cosponsors
1 original · 3 later
- Rep. David Kustoff (R-TN-8)· Original · Jun 4, 2025
- Rep. Claudia Tenney (R-NY-24)· Later · Dec 19, 2025
- Rep. Lateefah Simon (D-CA-12)· Later · Apr 14, 2026
- Rep. Nathaniel Moran (R-TX-1)· Later · Jul 21, 2026
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Small Biotech Innovation Act
Display title, Short title · Introduced in House
To amend title XI of the Social Security Act to establish a research and development-intensive small biotech manufacturer exception from the Medicare drug price negotiation program.
Official title · Introduced in House